Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

NYSE - LSE

RBGPF	0%	76.02	$
CMSC	-1.14%	19.28	$
RELX	1.16%	40.51	$
AZN	0.04%	184.45	$
BTI	1.37%	61.89	$
RYCEF	1.35%	17.8	$
GSK	0.52%	50.45	$
NGG	0.82%	84.29	$
RIO	-0.4%	82.95	$
BCE	0.37%	21.43	$
BP	0.87%	45.7	$
BCC	-0.79%	67.39	$
VOD	-0.78%	15.37	$
JRI	-1.21%	11.29	$
CMSD	-1.14%	19.29	$

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

BOULEVARD 10.03.2025

BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant.

Text size:

"Thanks to the diligent efforts of our regulatory team in securing these new registrations with the MHRA, we are now able to bring our safe and effective Microcyn-based products to the United Kingdom," said Amy Trombly, CEO of Sonoma. "The U.K. represents a significant new market for Sonoma, for both our wound care and dermatology products, and we are excited for the opportunities for growth that this new registration provides."

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected].

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.
[email protected]
Website: www.sonomapharma.com

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

R.Garcia--AT

Arizona Tribune - Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Featured

Kai Widdrington Withdraws from Strictly Come Dancing Due to Illness; Aljaž Škorjanec Steps In

Documentary Reveals How Screams Exposed Alleged Camgirl Exploitation Ring

Action Behavior Centers BCBAs and Teammates Volunteer Across San Antonio, Donating 271 Pounds of Food During First Hands In Week

#paid Earns Premier Creative Badge in the TikTok Marketing Partners Program